The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Trial Parameters
Brief Summary
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
Eligibility Criteria
Inclusion Criteria: * Histopathology or cytology confirmed the lung squamous cell carcinoma * Age ranging from 18 to 75 * Agree to participate in this study and sign an informed consent form * Treatment-naive tumor * According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor * Sufficient tissue/blood samples are available to meet research requirements * The ECOG PS score is 0-1 Exclusion Criteria: * Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form * Non-squamous NSCLC * Unresectable IIIa-IIIb tumor * Patients with solid organ or blood system transplantation * Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors * Patients with interstitial lung disease * Patients with acute or chronic infectious disease * Pregnant and lactating women * Patients who have und